ד"ר יאיר בר

  • סגל אקדמי קליני באונקולוגיה
אונקולוגיה סגל אקדמי קליני
ד"ר יאיר בר

Dr Jair Bar, MD PhD

Dr Jair Bar is an active physician, head of the Thoracic Oncology service at the Sheba Institute of Oncology. He is also the Deputy Director of the Insitute and the Head of the Israel Lung Cancer Group. Dr Bar heads a basic research lab, focusing on models of lung cancer, studying the tumor-immune system-host interactions and how these can be manipulated to eradiacate lung cancer. He is also a clinical investigator, leading a large number of clinical trials for lung cancer patients, using Immunotherapy and other tools.

Education

      Education

DEGREE

YEAR(s)

FIELD OF STUDY

Institute, Location

B.Sc.

1990-1993

Medicine

The Hebrew University-Hadassah School of Medicine, Jerusalem, Israel

M.D.

1993-1997

Medicine

 

Ph.D.

2000-2004

Molecular Biology

Weizmann Institute of Science, Rehovot, Israel

Specialist in Oncology

2004-2009

Medical and Radiation Oncology

Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

Fellowship of Thoracic Medical Oncology

2009-2011

Thoracic Medical Oncology

The Ottawa Hospital Cancer Centre, Ottawa, Canada

Additional Certificates:

Medical Specialist license, Oncology (Medical & Radiotherapy), Israel.      2009

License to practice medicine, Israel, Unrestricted (#30252)                           1998

 

Work / training positions:

2014-              Deputy Director, Institute of Oncology, Sheba Medical Center, Israel.

2013-              Chairman of the Israel Lung Cancer Group.

2011-              Head, Thoracic Oncology, Medical & Radiation Oncology, Institute of Oncology, Sheba Medical Center, Israel.

2011-              Head, Novel Therapeutics for Lung Cancer Lab, Institute of Oncology, Sheba Medical Center, Israel.

2009-2011     Clinical & Research Fellow, Medical Oncology, The Ottawa Hospital, Ottawa, ON, Canada.

2004-2009      Resident, Oncology (Medical and Radiotherapy), Sheba Medical Center, Israel.

2005-2008      Investigator, an independent research lab at the Sheba Cancer Research Center, Israel.

1998-2004       Physician (part-time), Internal Medicine, Sheba Medical Center, Israel.

1998-2000       Research fellow, the Weizmann Institute of Science, Israel.

 

Other activities:

Editorial board member of MEMO (Magazine of European Medical Oncology) since 2013.

Editorial board member of Annals of Thoracic Oncology Research since 2017.

PI on most industry-sponsored lung cancer trials in the Sheba Oncology Institute, since 2012.

PI and initiator of many clinical investigator initiated trials (latest; NCT01932229, NCT02938624).

Co-Investigator on clinical trials of the National Cancer Institute Canada – Clinical Trials Group (NCIC-CTG) 2009-2011.

Grant reviewer for Israel Science Foundation, ‘Israel Cancer Fund’, the Israeli Health Ministry Chief Scientist, 'The Netherlands Organization for Health Research and Development', ‘Bi-national Science Foundation’.

A reviewer for Lung cancer, Clinical Lung Cancer, PLOS ONE, Cancer Science, Cancer Microenvironment, J of Chemotherapy, Pharmaceutical Research, International Journal for Biotechnology, Molecular Biology Research and Expert Opinion on Drug Delivery journals.

Academic Appointments

Lung Cancer

Immunotherapy

Tumor-host interaction

Cancer microenvironment

Awards and Prizes

Peer-reviewed Publications:

Dagan A, Sella T, Urban D, Onn A, Bar J*, Segal G*. Low ALT is not associated with Increased Rate of Mortality in Patients with Advanced Lung Cancer. *equal contribution. Accepted to JCSM Clinical Reports, March 2017.

Appel S, Goldstein J, Perelman M, Rabin T, Urban D, Onn A, Shulimzon TR, Weiss I, Lieberman S, Marom EM, Golan N, Simanski D, Ben-Nun A, Lawrence YR, Bar J *, Symon Z * Definitive dose Chemo-radiation followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer Patients; Evaluation of Trimodality Strategy *equal contribution. Accepted to IMAJ Feb 2017.

Shiran I, Heller E, Jessel S, Kamer I, Meshulam I, Navon R, Urban D, #Onn A, #Bar J. NSCLC Patients with adenocarcinoma morphology have better prognosis than patients diagnosed with NSCLC favor adenocarcinoma. # equal contribution. In press Clinical Lung Cancer, Jan 2017. http://dx.doi.org/10.1016/j.cllc.2017.01.009.

Appel S, Lawrence YR, Goldstein J, Pfeffer RM, Weiss I, Rabin T, Felder S, Ben-Ayun M, Tzvang L, Alezra D, Simansky D, Ben-Nun A, Bar J, Symon Z. Stereotactic Ablative Body Radiation for Stage I Lung Cancer in Israel: A Retrospective Single-Center Report. IMAJ 2017 January; 19: 39-43.

Bar J, Gorn I, Hasim MS, Baghai T, Hanson JEL, Niknejad N, Perkins TJ, Stewart DJ, Sekhon HS, Villeneuve PJ and Dimitroulakos J. Induction of Activating Transcription Factor 3 is associated with cisplatin responsiveness in NSCLC: A potential predictive biomarker of response. Neoplasia. 2016 September; 18(9): 525–535.

Appel S, Goldstein JD, Symon Z, Lawrence Y, Bar J, Rabin T, Ben Ayun M, Davidson T, Ben Nun A. Does Pathologic Response to Neoadjuvant Chemoradiation to 60 Gy Predict Survival in Locally Advanced Non-Small Cell Lung Cancer? Int J Rad Onc Biol Phys 2016 Oct; 96(2): Sup E465.

Appel S, Lawrence YR, Bar J, Ben Nun A. Concomitant chemo-radiation to 60 Gy followed by surgery for locally advanced non-small cell lung cancer patients; evaluation of trimodality strategy. J Thor Onc. 2016 April; 11(4): Sup S109. Abstract 122P ELCC 2016.

Leibowitz-Amit R, Shapira-Frommer R, Golan T, Korach L, Israel A, Shalem Y, Shacham-Shmueli E, Ben-Ami E, Hausner D, Zach L, Nili Gal-Yam E, Kaufman B, Onn A, Urban D, Bar J, Berger R. Initial clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single institution. Eur J Cancer, September 2015 51(sup 3); S111.

Feinberg T, Alkob L, Herbig J, Cancilla J, Torrecilla J, GaiMor N, Bar J, Ilouze M, Haick H, Peled N. Cancerous glucose metabolism in lung cancer – evidence from exhaled breath analysis. Journal of Breath Research, 2016 June; 10(2): doi:10.1088/1752-7155/10/2/026012.

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Onn A, Uziely B, Peretz T. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer. British Journal of Cancer 2016; 114: 469–476. doi:10.1038/bjc.2016.7.

Ben Nun A, Simansky D, Rokah M, Zaytlin N, Ben Avi R, Soudack M, Golan N, Apel S, Bar J, Yelin A. Hybrid video-assisted and limited open (VALO) resection of superior sulcus tumors. Surgery Today. 2016; 46: 686. doi:10.1007/s00595-015-1225-0.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, and Bradbury PA. Angiotensin Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group study BR.24. Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13. PubMed PMID: 26081815.

Bar J, Botser D, Navon R, Peled N, Biran H, Nili Gal-Yam E, Ben-Arieh S, Raskin S, Onn A; A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. J Clin Oncol 33, 2015 (suppl; abstr e19031).

Bar J, Gottfried M, Dudnik J, Flex D, Keren-Rosenberg SP, Agbarya A, Onn A, Moskovitz MT, Maimon N, Lazarev I, Peled N, Popovits-Hadari N, Biran H, Urban D, Herscovici L, Wollner M. Prognostic impact of first treatment choice in EGFR mutant non-small cell lung cancer (mNSCLC) patients (pts) per mutation type; retrospective analysis. J Clin Oncol 33, 2015 (suppl; abstr e19120).

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Uziely B, Peretz-Yablonski T. New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung cancer: Implications for diagnosis, follow-up, and prognosis. J Clin Oncol 33, 2015 (suppl; abstr 7570).

Katanov C, Lerrer S, Liubomirski Y, Lieder-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D and Ben-Baruch A. Regulation of the inflammatory profile of stromal cells in human breast cancer: Prominent roles for TNF-alpha and the NF-kappaB pathway. Stem Cell Research & Therapy 2015 May; 6:87  doi:10.1186/s13287-015-0080-7.

Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart D, Goss G, Dimitroulakos J. Cyclin dependent kinase 6 down-regulation as a potential mechanism of acquired cisplatin resistance in non-small cell lung carcinoma. Clin Lung Cancer. 2015 Nov;16(6):e121-9. doi: 10.1016/j.cllc.2015.01.008. Epub 2015 Feb 3. PubMed PMID: 25703099.

Sella T, Botser D, Navon N, Biran H, Tenenbaum S, Urban D, Onn A, Bar J. Preferences for disclosure of disease related information among thoracic cancer patients. Lung Cancer 2015 Apr;88(1):100-3. doi: 10.1016/j.lungcan.2015.01.021. Epub 2015 Jan 31.

Agbarya A, Melamed-Frank M,  Kaidar-Person O,  Goldberg-Cohen I, Nasrallah H, Wollner M,   Bar J, Rennert G, Lejbkowicz F. Getting out of a wheelchair: an uncommon insertion

mutation in exon 19 of EGFR responsive to erlotinib. SpringerPlus. 2014; 3:507
DOI: 10.1186/2193-1801-3-507.

Bar J, Cyjon A, Dov F, Sorotsky H, Biran H, Dudnik J, Peylan-Ramu N, Peled N, Nechushtan H, Gips M, Katsnelson R, Keren SR, Merimsky O, Onn A, Gottfried M, on behalf of the Israeli Lung Cancer Group. EGFR mutation testing in advanced non-small cell lung cancer. Lung May 2014; 192(5): 759-763. DOI 10.1007/s00408-014-9604-7.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Zadok O, Cohen Y, Perelman M, Barshack I, Yarden RI, Simansky D, Ben Nun A, Onn A. Evaluation of EGFR, KRAS and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLC). MEMO, 2014 February; 7(1): 10-15.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Perelman M, Ben Nun A, Simansky D, Yellin A, Urban D, Onn A. Genetic mutations screen in early non small cell lung cancer (NSCLC) specimens. Clinical Lung Cancer, 2014 March, 15(2): 159–165.

Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson J, Jürgensmeier JM, Goss GD. Correlation of LDH isoenzyme profile with outcome in advanced colorectal cancer patients treated with chemotherapy and bevacizumab or cediranib (HORIZON I study). Clinical Colorectal Cancer, March 2014; 13(1): 46–53.

Shlomi D, Onn A, Gottfried M, Bar J, Biran H, Ilouze M, Dvir A, Nechushtan H, Soussan-Gutman L, Peled N. Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer. Journal of Cancer Therapy, 2013, 4, 54-58

Bar J, Ding K, Zhao H, Laurie SA, Shepherd F, Addison C, Goss GD, Dimitroulakos J, Bradbury PA. Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. J Clin Oncol 31, 2013 (suppl; abstr 8048). [IF 2011: 18.372]

Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of postoperative radiotherapy in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013 Jul;8(7):940-6.

Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson J, Jürgensmeier JM, Goss GD. Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED). J Clin Oncol. 30, 2012 (suppl; abstr e13541). [IF 2011: 18.372]

Biran H, Perelman M, Bar  J, Zwas TS. Somatostain receptor (SSTR)-targeted therapy in pulmonary large-cell neuroendocrine carcinoma (LCNEC) patients with intermediate proliferation rate (PR). J Clin Oncol 30, 2012 (suppl; abstr e17509). ). [IF 2011: 18.372].

Shiran I, Borshteen R, Urban D, Onn A, Biran H, Bar J. The efficacy of pemetrexed-based treatment for advanced non-small cell lung cancer (NSCLC), as correlated with the pathologic features of tumors. Journal of Thoracic Oncology. 2012 June; 7 Sup 1, S45.

Bar J, Ng D, Moretto P, Goss DG, Sun A, MacRae R, Laurie S, Leighl N and Nicholas G. Chemoradiotherapy for recurrent NSCLC; retrospective database analysis of two large cancer centers. Clinical Lung Cancer. 2013 March; 14(2). 200-4.

Vickers MM*, Bar J*, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JEL, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IAJ, Goss DG and Dimitroulakos J. Stage-dependant differential expression of microRNAs in colorectal cancer: Potential role as markers of metastatic disease. Clinical and Experimental Metastasis. 2012 Feb; 29(2). 123-132. *Equal contribution. [IF 2010: 4.113]

Gomes M, Souza C, Bar J, Sekhon H. Interdisciplinary site-specific didactic meetings: Interdisciplinary site-specific didactic meetings: Addressing competency-based education and program-based clinical services. International Conference on Residency Education 2011, Royal College of Physicians and Surgeons of Canada. Open Medicine. September 21, 2011. Vol. 5(3), pp.S10, abstract 159.

Bar J, Gorn-hundermann I, Reid S, O’Brien A, Niknejad N, Goss GD, Dimitroulakos J. Activating transcription factor 3 (ATF3) as a potential biomarker of platinum sensitivity in non-small cell lung cancer (NSCLC). J Clin Oncol. 29: 2011 (suppl; abstr e21012). [IF 2011: 18.372]

Bar J, Perez-Iratxeta C, Gorn-hundermann I, Reid S, Goss G, Dimitroulakos J. microRNA (miR) analysis as a tool for discovering platinum resistance mechanisms in non-small cell lung cancer (NSCLC). 2011 Proceedings of the American Association for Cancer Research. Abstract #4949.

Vickers MM, Asmis T, Jonker D, Maroun JA, Yarom N, Bar J, Gorn-Hundermann I, Daneshmand M, Dimitroulakos J. Metastasis suppressing/promoting microRNA expression in primary and metastatic colorectal cancer. Ann Oncol. 2010 Oct; 21, sup (8): viii49 (102P).

 

Gorn I, Bar J, Vickers MM, Dimitroulakos J. Optimization of microRNA (miRNA) extraction from formalin fixed paraffin embedded (FFPE) colorectal and lung cancer tissues, and validation of a microRNA internal control.  Ann Oncol. 2010 Oct; 21, sup (8): viii60 (147).

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C and Barshack I. Breast cancer Her2 equivocal cases: is there an alternative to FisH testing? a Pilot study Using two Different antibodies sequentially. IMAJ, 2010 June; 12: 78-81.

Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser M, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunology Immunotherapy, 2010 February; 59(2): 215-230. [IF 3.728 2007].

Bar J., Feniger-Barish R., Moskovits N, Lukashchuk N, Goldfinger N, Rotter V, Goss G, Oren M. Cancer cells suppress p53 in adjacent fibroblasts. Journal of Thoracic Oncology 2009 September; 4(9) Sup (1): S605.

Bar J , Feniger-Barish R., Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M, Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 2009 Feb 12;28(6):933-6. [IF 6.44 
#14/132 Oncology 2007].

Gluck I, Simon A.J, Catane R, Pfepfer R, Schachter J, Rechavi G, and Bar J. Malignant Melanoma patients' germ-line analysis of Thymidine/Guanidine polymorphism in position 309 of the promoter of the Mdm2 gene. Melanoma Res. 2009 August; 19(4): 199-202. [IF 2.077, 15/39 Dermatology, Oncology].

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, and Jacob Schachter J. Concurrent Chemobiotherapy with Cisplatin, Dacarbazine, decrescendo Interleukin-2 and Interferon alpha2b in Patients with Metastatic Melanoma. Oncology Reports. 2008 Dec;20(6):1533-8. [IF 1.597].

Moskovitz N, Kalinkovich A, Bar J, Lapidot T and Oren M. p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006 Nov 15;66(22):10671-6 [IF 7.656, #10/127 Oncology 2006].

Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V and Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 2006 Jan 19;25(3):359-69 [IF 6.582, #12/127 Oncology 2006].

Bar J, Lukaschuk N, Zalcenstein A, Seger R, Oren M. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death and Differentiation. 2005 Jun 3; 12: 1578–87 [IF 7.463, #22/125 Cell Biology 2006].

Bar J, Cohen-Noyman E, Geiger B, Oren M. Attenuation of the p53 response to DNA damage by high cell density. Oncogene. 2004 Mar 18; 23(12):2128-37 [IF 6.582, #12/127 Oncology 2006].

Lavon I, Pikarsky E, Gutkovich E, Goldberg I, Bar J, Oren M, Ben-Neriah Y. Nuclear Factor-kappaB Protects the Liver against Genotoxic Stress and Functions Independently of p53. Cancer Res. 2003 Jan 1; 63(1):25-30 [IF 7.656, #10/127 Oncology 2006].

PhD thesis: Role of p53 in tumor-host interactions. Mentor: Moshe Oren, Weizmann Institute of Science. Approved Dec 2004.

 

Book chapters, editorials, reviews, letters:

Onn A, Bar J, Herbst Roy S. Angiogenesis inhibition and lung cancer therapy. Editorial. Lancet Oncol. 2014 Feb; 15(2): 124 – 125.

Shlomi D, Pekar M, Iluze M, Bar J, Biran H, Navon R, Onn A, Peled N. The Diagnostic Puzzle of EML4-ALK Rearrangement in Lung Cancer. Review. The Journal of OncoPathology. 2013 Jul; 1(2): 103-110(8).

Bar J, Urban D, Borshtein R, Nechushtan H, Onn A. EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy. Editorial. Chin Clin Onc. 2012 Dec 11. DOI: 10.3978.

Bar J, Shiran I, Urban D, Agbarya A, Onn A. Anti-angiogenic treatments in advanced NSCLC: back to the drawing board. Editorial. J Thorac Dis. 2012 Oct 18. DOI: 10.3978.

Bar J, Goss G. Tumor vasculature as a therapeutic target in Non-small Cell Lung Cancer. Journal of thoracic oncology. Review. March 2012; 7(3): 609–620. [IF 4.040, #50/185 Oncology,

#7/46 Respiratory System].

Bar J, Herbst R and Onn A. Overcoming resistance to EGFR TKIs in lung cancer. Review. Clinical Lung Cancer. On line Dec 2011 [IF 2.393].

Bar J, Wheatley Price P. Advances in liposomal formulations for targeting lung cancer (2011). In: Ed. Souto EB. Lipid Nanocarriers in Cancer Diagnosis and Therapy. Special handbook edition. Shrewsbury, UK: iSmithers Rapra Publishing. pp. 257-278.

Livneh J, Waddington K and Bar J. Addressing Safety Issues of Health Care Personnel, Family Members, and the Environment. Letter. Journal of Clinical Oncology. 2010 February 16; published online [IF 17.157].

Bar J, Moskovits N and Oren M. Involvement of stromal p53 in tumor-stroma interactions. Review. Seminars in Cell and Developmental Biology. 2010 February; 21(1):47-54 [IF 4.528].

Bar J, Onn A and Herbst RS. Molecular Events Surrounding the Angiogenic Switch of Lung Cancer. In: Eds. Pass H. Carbone DP, Johnson DH, Minna JD, Scagliotti GV and Turrisi AT III. Principles and Practice of Lung Cancer, the official reference text of the IASLC:, 4th Ed., Lippincott, Philadelphia, PA. 2010.

Bar J, Herbst RS, and Onn A. Targeted drug delivery strategies to treat lung metastasis. Review. Expert Opinion on Drug Delivery. 2009 October; 6(10):1003-1016 [IF 3.345, 2009].

Bar J, Herbst RS, and Onn A. Multi-Targeted Therapeutics in Lung Cancer: New Clinical Data. Review. Clinical Lung Cancer. 2008 May 15;9(sup3):S92-S99.

Bar J and Onn A. Combined anti-proliferative /anti-angiogenic strategies for cancer. Review. Expert Opinion on Pharmacotherapy. 2008 Apr;9(5):701-15. [IF 2.077, 123/216 Pharmacology & Pharmacy 2008].

Frommer-Shapira R, Bar J, Kuchuk, I, Catane, R and Schachter, J. Chemobiotherapy in metastatic melanoma patients: the Sheba experience. Melanoma Research.

2007 Feb; 17(1): A27-A28.

Bar J, Ehrenfeld M, Rozenman J, Perelman M, Sidi Y, Gur H. Pulmonary-renal syndrome in systemic sclerosis. Review. Semin Arthritis Rheum. 2001 Jun;30(6):403-10.

אוניברסיטת תל-אביב, רחוב חיים לבנון 30, 6997801.
UI/UX Basch_Interactive